Core Viewpoint - Rosen Law Firm is reminding investors who purchased Dow Inc. securities between January 30, 2025, and July 23, 2025, of the upcoming lead plaintiff deadline on October 28, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Dow securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 28, 2025 [2]. - The lawsuit alleges that Dow made false and misleading statements regarding its financial flexibility and the impact of macroeconomic factors on its business [4]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3]. - The firm achieved the largest securities class action settlement against a Chinese company at the time and has been consistently ranked among the top firms for securities class action settlements since 2013 [3]. - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its capability in handling significant cases [3].

Core Viewpoint - The article discusses a class action lawsuit against Dow Inc. for alleged violations of the Securities Exchange Act of 1934, with a focus on misleading statements regarding the company's financial health and ability to manage macroeconomic challenges during the specified class period from January 30, 2025, to July 23, 2025 [1][4]. Group 1: Allegations and Financial Performance - The lawsuit claims that Dow overstated its ability to handle macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [4]. - It is alleged that the true impact of competitive pressures, declining global sales, and product oversupply on Dow's business was understated [4]. - On June 23, 2025, BMO Capital downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00, which led to a stock price drop of over 3% [5]. - Dow reported a non-GAAP loss per share of $0.42 for Q2 2025, significantly worse than the expected loss of approximately $0.17 to $0.18, with net sales of $10.1 billion, a 7.3% year-over-year decline [6]. - Following the disappointing Q2 results, Dow's stock price fell by more than 17%, and the company announced a dividend cut from $0.70 to $0.35 per share [6]. Group 2: Legal Process and Representation - Investors who purchased Dow securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to represent the interests of all class members [7]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [7]. Group 3: About the Law Firm - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8]. - The firm has been recognized for obtaining significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [9].

Core Viewpoint - A class action lawsuit has been filed against Dow, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial condition during the specified class period from January 30, 2025, to July 23, 2025 [3][7]. Allegation Details - Defendants overstated Dow's ability to manage macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [3]. - The negative impacts of competitive pressures, declining global sales, and product oversupply on Dow's business were understated [3]. - Public statements made by the defendants were materially false and misleading throughout the class period [3]. Next Steps - Investors who purchased Dow shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 28, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents investors in complex litigation across various courts [5].

Core Viewpoint - A class action lawsuit has been filed against Dow Inc. on behalf of shareholders who purchased securities during the specified class period from January 30, 2025, to July 23, 2025 [1] Company Summary - Dow Inc. is identified as a materials science company [1] - The lawsuit is being led by Rosen Law Firm, which specializes in investor rights [1] Allegations Summary - The allegations under investigation by Rosen Law Firm pertain to the actions of Dow Inc. during the class period [1]

Group 1: Federal Reserve Policy Shift - The Federal Reserve is transitioning from prioritizing inflation control to focusing on growth, with a consensus expectation of interest rate cuts in October and December, indicating a potential continuous rate-cutting cycle [1] - This policy adjustment is driven by reduced inflation pressures and signs of weakness in the job market, rather than economic panic [1] Group 2: Impact on Pharmaceutical and Chemical Industries - The interest rate cuts will lower financing costs and improve global liquidity, significantly benefiting the pharmaceutical sector, especially innovative drug and CXO companies reliant on financing for R&D [3] - The pharmaceutical sector is expected to see increased capital flow towards emerging market assets, supported by recent policy events and conferences [3] - In contrast, the chemical industry may experience a replenishment cycle, stimulating capital expenditures and production investments, but faces challenges from rising raw material costs and weak global demand [3] Group 3: Company Performance Highlights - Sanofi expects high single-digit sales growth and low double-digit earnings per share growth driven by innovation, despite challenges in its vaccine business [4] - Roche reported a 7% year-on-year sales increase to 45.9 billion Swiss francs, primarily driven by its pharmaceutical division, which saw a 9% increase due to high demand for key innovative drugs [5] - Dow Inc. experienced an 8% year-on-year decline in net sales, with all operational segments showing a downturn, although cash flow improved significantly due to working capital optimization [5] Group 4: Trends in the Pharmaceutical and Chemical Sectors - Chinese companies are gaining global competitiveness in the pharmaceutical sector, particularly in the CXO field, which is becoming a crucial base for global pharmaceutical innovation [5] - Traditional sectors like raw material and chemical pharmaceuticals must upgrade technology and collaborate across the supply chain to avoid market share and profit erosion [5] - The future competitiveness of the global market and China's pharmaceutical and chemical industries will increasingly depend on technological innovation and global operational capabilities [6]

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF†) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 28, 2025 to file lead plaintiff applications in a securities class action lawsuit against Dow Inc. (NYSE: DOW), if they purchased the Company's securities between January 30, 2025 and July 23, 2025, inclusive (the "Class Period†). This action is pending in the United States District Court f. ...

Market Overview - The U.S. stock market reached unprecedented highs on October 24, 2025, with all three major indexes setting new records due to a cooler-than-expected inflation report, strong corporate earnings, and easing global trade tensions [1][3][9] - The S&P 500 climbed approximately 0.9% to 1%, surpassing the 6,800-point mark for the first time, while the Dow Jones Industrial Average rose around 1.1% or 519 points, and the Nasdaq Composite advanced approximately 1.3% to 1.31% [2] Sector Performance - The technology and semiconductor sectors were significant contributors to the market gains, with companies like Advanced Micro Devices (AMD) surging approximately 6.5% and Intel (INTC) seeing shares rise between 1.2% and 3.8% due to strong demand driven by the AI boom [4][12] - Energy stocks also performed well, boosted by rising crude oil prices following new U.S. sanctions on major Russian oil producers [4] - Defensive sectors such as consumer staples, healthcare, and utilities experienced modest movements or slight declines, indicating a "risk-on" market sentiment [4] Company News - Ford Motor (F) shares increased by 11.1% after reporting stronger-than-expected profits [7] - Dow Inc. led the S&P 500 with a jump of over 12% after exceeding consensus estimates for adjusted operating EBITDA in Q3 [12] - HCA Healthcare (HCA) saw its shares rise over 4% after significantly surpassing Q3 earnings expectations [12] - Conversely, Newmont Mining (NEM) fell 4.3% despite reporting stronger-than-expected profits, and Deckers Outdoor (DECK) plunged 12.5% to 14% after providing a weaker-than-expected outlook [12]

We recently published Why These 10 Stocks are Soaring by Double Digits. Dow Inc. (NYSE:DOW) is one of the best performers on Thursday. Shares of Dow Inc. (NYSE:DOW) climbed by 12.95 percent on Thursday to end at $24.51 apiece despite a dismal earnings performance in the third quarter of the year, as investors took heart from lower-than-expected losses. In an updated report, Dow Inc. (NYSE:DOW) clocked in a $0.19 loss per share, lower than the $0.30 as expected by analysts, on a net income of $124 million ...

Core Viewpoint - The Dow class action lawsuit alleges that Dow Inc. and its executives made misleading statements regarding the company's financial health and ability to manage macroeconomic challenges, leading to significant investor losses during the specified class period [3][4][5]. Summary by Sections Class Action Details - The class action lawsuit, titled Sarti v. Dow Inc., is open for investors who purchased Dow securities between January 30, 2025, and July 23, 2025, to seek appointment as lead plaintiff by October 28, 2025 [1][6]. Allegations Against Dow - The lawsuit claims that Dow overstated its ability to handle macroeconomic and tariff-related challenges, and understated the negative impacts of competitive pressures, softening global sales, and product oversupply on its business [3][4]. - On June 23, 2025, BMO Capital downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00, which was followed by a stock price drop of over 3% [4]. - Dow reported a non-GAAP loss per share of $0.42 for Q2 2025, significantly worse than the expected loss of approximately $0.17 to $0.18, with net sales of $10.1 billion reflecting a 7.3% year-over-year decline [5]. Financial Impact - Following the disappointing Q2 results, Dow announced a dividend cut from $0.70 to $0.35 per share, citing the need for financial flexibility in a challenging macroeconomic environment, which led to a stock price decline of over 17% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Dow securities during the class period to seek lead plaintiff status, which enables them to act on behalf of all class members [6]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7][8].

Financial Performance - The Company reported net sales of $10.0 billion in Q3 2025, down 8% from $10.9 billion in Q3 2024, with declines across all operating segments[199]. - Net sales in Q3 2025 were $10.0 billion, down 8% from $10.9 billion in Q3 2024, with local price down 8% and volume down 1%[203]. - For the first nine months of 2025, net sales were $30.5 billion, a decrease of 6% from $32.6 billion in the same period last year, with local price down 6%[204]. - Cost of sales in Q3 2025 was $9.2 billion, down from $9.8 billion in Q3 2024, with COS as a percentage of net sales increasing to 92.7% from 90.2%[205]. - Net income available for Dow Inc. common stockholders was $62 million, or $0.08 per share, in Q3 2025, down from $214 million, or $0.30 per share, in Q3 2024[223]. - The company's share of equity in losses of nonconsolidated affiliates was $72 million in Q3 2025, compared to earnings of $2 million in Q3 2024[212]. - Interest expense and amortization of debt discount increased to $221 million in Q3 2025 from $199 million in Q3 2024[215]. - Net income attributable to noncontrolling interests was $62 million in Q3 2025, compared to $26 million in Q3 2024[221]. Cost Management and Restructuring - The Company announced targeted cost actions to reduce structural costs by $1 billion over the next two years, including a workforce reduction of approximately 1,500 roles[192]. - The company recorded pretax restructuring charges of $591 million in Q2 2025, with additional charges of $23 million in Q3 2025[210]. - The 2025 Restructuring Program is expected to incur additional cash expenditures of approximately $650 million over the next four years[286]. Capital Expenditures and Investments - Dow's capital expenditures for 2025 were reduced to $2.5 billion from an original plan of $3.5 billion due to ongoing macroeconomic volatility[193]. - Capital expenditures for the first nine months of 2025 were $1,911 million, down from $2,173 million in the same period of 2024, with full-year capital spending expected to be approximately $2.5 billion[250]. Cash Flow and Liquidity - Cash provided by operating activities for continuing operations was $1,130 million in Q3 2025, up from $800 million in Q3 2024, driven by working capital improvements[201]. - Cash provided by operating activities from continuing operations was $764 million in the first nine months of 2025, down from $2,092 million in the same period of 2024[246]. - The Company had cash and cash equivalents of $4,609 million at September 30, 2025, up from $2,189 million at December 31, 2024[244]. - Current assets increased to $19,646 million in September 2025 from $16,590 million in December 2024, while current liabilities decreased to $10,104 million from $10,288 million[248]. - Net working capital rose to $9,542 million in September 2025, up from $6,302 million in December 2024, resulting in a current ratio of 1.94:1[248]. - The company maintained cash and committed liquidity of $14.5 billion as of September 30, 2025, with no long-term debt maturities due until 2027[259]. Debt and Financing - Total debt as of September 30, 2025, was $18,255 million, with net debt at $13,149 million, reflecting a net debt to total capitalization ratio of 40.8%[270]. - The Company issued $1 billion of senior unsecured notes in Q1 2025, with $943 million tendered and retired, resulting in a pretax loss of $60 million[273][274]. - In Q3 2025, the Company issued $1.4 billion of senior unsecured notes and recognized a pretax loss of $18 million on the early extinguishment of debt[275]. - As of September 30, 2025, TDCC's long-term debt obligations totaled $18.353 billion, with expected cash requirements for interest at $13.803 billion[290]. Market Risk and Financial Instruments - The company provided quantitative and qualitative disclosures about market risk in its annual report for the year ended December 31, 2024[301]. - Financial instruments utilization and sensitivity analysis were discussed in the combined Dow Inc. and TDCC Annual Report[301]. - The report emphasizes the importance of understanding the sensitivity of financial instruments[301]. - The company highlighted its approach to managing market risk through various financial instruments[301]. - The annual report includes a comprehensive analysis of market risk factors affecting the company[301]. - The sensitivity analysis aims to provide insights into potential financial impacts[301]. - The company aims to enhance transparency regarding its financial risk management strategies[301]. - The disclosures are intended to inform stakeholders about the company's risk exposure[301]. - The report is part of the company's commitment to regulatory compliance and investor communication[301]. Dividends and Shareholder Returns - The Company declared a quarterly dividend of $0.35 per share, a 50% reduction compared to the previous quarter, reflecting a balanced capital allocation approach[196]. - For the first nine months of 2025, the Company declared dividends totaling $1,225 million and paid $1,237 million to common stockholders[280]. - The Company has a share repurchase program with $931 million remaining available for repurchases as of September 30, 2025, with no repurchases made in 2025[282]. Segment Performance - Packaging & Specialty Plastics net sales were $4,891 million in Q3 2025, down 11% from $5,516 million in Q3 2024, with local price down 10%[227]. - Operating EBIT for Packaging & Specialty Plastics was $199 million in Q3 2025, a decrease of $419 million from $618 million in Q3 2024, primarily due to lower integrated margins[229]. - Industrial Intermediates & Infrastructure net sales were $2,834 million in Q3 2025, down 4% from $2,962 million in Q3 2024, with local price down 8%[232]. - Operating EBIT for Industrial Intermediates & Infrastructure was a loss of $47 million in Q3 2025, an improvement of $6 million from a loss of $53 million in Q3 2024[233]. - Performance Materials & Coatings net sales were $2,082 million in Q3 2025, down 6% from $2,214 million in Q3 2024, with local price down 5%[237]. - Operating EBIT for Performance Materials & Coatings was $80 million in Q3 2025, down $60 million from $140 million in Q3 2024, primarily due to margin compression[238]. Claims and Legal Matters - The Company reported 6,501 unresolved asbestos-related claims as of September 30, 2025, an increase from 5,370 in 2024[299]. - Credit ratings for TDCC as of September 30, 2025, included BBB from Fitch, Baa2 from Moody's, and BBB from Standard & Poor's, with a negative outlook from Moody's and S&P[277][278].